Today, L’Oréal Groupe has announced a strategic move to acquire a majority stake in the renowned British skincare brand, Medik8, which will become part of its prestigious Luxe Division.
According to report, founded by scientist Elliot Isaacs, Medik8 has gained acclaim for its groundbreaking Crystal Retinal serum and CSA Philosophy©, emphasizing Vitamin C and sunscreen by day, and Vitamin A by night. This acquisition underscores L’Oréal’s commitment to enhancing its Luxe portfolio with scientifically-driven skincare solutions known for their effectiveness and accessibility.
Inflexion, a leading European private equity firm, will retain a minority shareholding, while Medik8’s founder will continue to serve on the board alongside the existing management team, ensuring continuity in leadership. The brand’s success is attributed to its blend of professional-grade formulations and an expanding omni-channel retail presence across Europe and the US.
Cyril Chapuy, President of L’Oréal LUXE, expressed enthusiasm about integrating Medik8 into the L’Oréal family, highlighting the brand’s potential for global expansion. “We are delighted to welcome Medik8 to the L’Oréal family,” Chapuy stated. “This partnership aligns perfectly with our strategy to offer premium skincare solutions that deliver visible results.”
Simon Coble, CEO of Medik8, shared his excitement about the collaboration, emphasizing shared values in innovation and scientific rigor. “I am delighted to join forces with L’Oréal,” Coble said. “Together, we look forward to expanding Medik8’s reach and introducing our innovative products to a wider audience.”
The transaction is expected to finalize in the coming months pending regulatory approvals, marking a significant milestone in L’Oréal’s strategy to bolster its presence in the premium skincare market.
